- Conditions
- Exfoliation Syndrome, Glaucoma, Ocular Hypertension
- Interventions
- Latanoprost with Pilocarpine vs Timolol or Cosopt
- Drug
- Lead sponsor
- The New York Eye & Ear Infirmary
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 277 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Open Angle Glaucoma
- Interventions
- Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
- Drug
- Lead sponsor
- Prairie Eye Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Springfield, Illinois
- Conditions
- Scleral Buckling
- Interventions
- Timolol-dorzolamide (Glaucoma drops), standard post-operative topical drops
- Drug
- Lead sponsor
- Jason Hsu, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glaucoma
- Interventions
- fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Open-Angle Glaucoma
- Interventions
- bimatoprost 0.03%, dorzolamide 2%/timolol maleate 0.5% fixed combination, placebo
- Drug
- Lead sponsor
- Pharmaceutical Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Mt. Pleasant, South Carolina • Houston, Texas
- Conditions
- Glaucoma
- Interventions
- Dorzolamide 2%-timolol 0.5%, Brimonidine 0.2%-0.5% timolol 0.5
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Macular Hole, Retinal Detachment
- Interventions
- Dorzolamide 2%-timolol 0.5% topical eyedrops
- Drug
- Lead sponsor
- Mid Atlantic Retina
- Other
- Eligibility
- Not listed
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania